Cancer Res. 1987 Apr 1;47(7):1957-61.

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.

Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AM, Jeffcoate SL, Coombes RC.

Abstract

4-Hydroxyandrostenedione (4-OHA) is a potent inhibitor of estrogen production by aromatase and causes suppression of plasma estradiol levels and disease regression in postmenopausal breast cancer patients. Groups of patients were given p.o. or parenteral 4-OHA, and plasma estradiol and 4-OHA levels were measured to enable the delineation of the minimal effective dose and optimal therapeutic regimen. A single injection of 500 mg i.m. suppressed estradiol levels to a mean 36.3 +/- 3.3% (SE) (n = 14) of base line after 4 to 7 days and maintained this suppression in six of seven patients for greater than 14 days. The half-life of 4-OHA was approximately 8 days, and when the level had fallen to less than 3 ng/ml, estradiol levels began to rise. Similar suppression was achieved by a single i.m. injection of 125 mg of 4-OHA and by 500 mg of 4-OHA p.o. daily after 1 wk, but escape from suppression was more rapid.

PMID:: 3815384; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

Publication Types

Comparative Study

MeSH Terms

Substances

LinkOut - more resources

Molecular Biology Databases

Libraries

LinkOut Holdings

Supplemental Content

Related citations

Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. [Cancer Res. 1989]
Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L, Hedley A, Coombes RC. Cancer Res. 1989 Mar 1; 49(5):1306-12.
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. [Cancer Res. 1986]
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
Goss PE, Powles TJ, Dowsett M, Hutchison G, Brodie AM, Gazet JC, Coombes RC. Cancer Res. 1986 Sep; 46(9):4823-6.
4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer. [Eur J Cancer. 1992]
4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.
Coombes RC, Hughes SW, Dowsett M. Eur J Cancer. 1992; 28A(12):1941-5.
Review Aromatase inhibitors: basic and clinical studies. [J Steroid Biochem. 1987]
Review Aromatase inhibitors: basic and clinical studies.
Brodie AM, Coombes RC, Dowsett M. J Steroid Biochem. 1987; 27(4-6):899-903.
Review Aromatase and other inhibitors in breast and prostatic cancer. [J Steroid Biochem Mol Biol. 1990]
Review Aromatase and other inhibitors in breast and prostatic cancer.
Brodie AM, Banks PK, Inkster SE, Son C, Koos RD. J Steroid Biochem Mol Biol. 1990 Dec 20; 37(6):1043-8.

See reviews... See all...

Cited by 27 PubMed Central articles

Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. [J Clin Oncol. 2010]
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, et al. J Clin Oncol. 2010 Mar 1; 28(7):1161-7. Epub 2010 Feb 1.
Review Deficits in plasma oestradiol measurement in studies and management of breast cancer. [Breast Cancer Res. 2005]
Review Deficits in plasma oestradiol measurement in studies and management of breast cancer.
Dowsett M, Folkerd E. Breast Cancer Res. 2005; 7(1):1-4. Epub 2004 Oct 28.
Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]. [Breast Cancer Res. 2004]
Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165].
Atkinson C, Warren RM, Sala E, Dowsett M, Dunning AM, Healey CS, Runswick S, Day NE, Bingham SA. Breast Cancer Res. 2004; 6(3):R170-9. Epub 2004 Feb 24.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast...
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.
Cancer Res. 1987 Apr 1 ;47(7):1957-61.

PubMed
Colocalization of estrogen and progesterone receptors with an estrogen-regulated...
Colocalization of estrogen and progesterone receptors with an estrogen-regulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue.
Breast Cancer Res Treat. 1990 Oct ;16(3):243-51.

PubMed
Estimation of the duration of a pre-clinical disease state using screening data.
Estimation of the duration of a pre-clinical disease state using screening data.
Am J Epidemiol. 1983 Dec ;118(6):865-86.

PubMed
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuv...
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst. 1998 Sep 16 ;90(18):1371-88.

PubMed
Effect of folinic acid on fluorouracil activity and expression of thymidylate sy...
Effect of folinic acid on fluorouracil activity and expression of thymidylate synthase.
Semin Oncol. 1992 Apr ;19(2 Suppl 3):16-25.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Libraries

Supplemental Content

Related citations

Cited by 27 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information